Skip to main content
letter
. 2020 Jul 11;10(3):e50. doi: 10.1002/ctm2.50

Figure 2.

Figure 2

Notopterol improves the cognitive decline in APP/PS1 mice. A, Representative water maze traces of WT mice (left), APP/PS1 mice (middle), and Notopterol‐treated (right) APP/PS1 mice on day 6. B, Analysis of the MWM test of WT, Notpterol‐treated, or without treated APP/PS1 mice. C, The levels of Aβ40 and Aβ42 in hippocampal and cortes in APP/PS1 mice. D, The level of Aβ42 in the cortex of APP/PS1 mice was positively correlated with memory impairment. E, Immunohistochemistry staining of deposited Aβ in APP/PS1 mice and Notopetrol (40 mg/kg) treated APP/PS1 mice; scale bars, 100 μm and 500 μm. F, Western blot of ADAM10, BACE1, ADAM17, p‐GSK3β, GSK3β, p‐tau, and tau in hippocampus of APP/PS1 mice and Notopetrol‐treated (40 mg/kg) APP/PS1 mice. Quantitative data are shown in Figure S4. G, Immunohistochemistry staining of phosphorylated tau in cortex of APP/PS1 mice and Notopetrol‐treated (40 mg/kg) APP/PS1 mice; scale bars, 50 μm. The error bars represent the SD. (*P < 0.05, **P < 0.01 and ***P < 0.001, other comparisons were not significant; One‐way analysis of variance followed by Turkey's post hoc multiple‐comparisons test)